查詢結果分析
相關文獻
- 臺灣B型肝炎防治
- Immunogenicity and Reactogenicity of Two Recombinant Hepatitis B Vaccines in Healthy Adolescents on Two-dose Schedule
- Control of Hepatitis B Virus Infection by Vaccination: The Taiwan Experience
- B型肝炎防治計畫在臺灣憶往
- Immunogenicity of Hepatitis B Vaccine in Chinese School Children: A Comparison of Two Plasma-derived Vaccines
- Immune Response to Hepatitis B Vaccine in Subjects Positive for Serum Hepatitis B Core Antibody Alone
- AIDS、省府虛級化、與B型肝炎疫苗--科學知識在臺灣的一種社會建構歷程
- 新竹區國小學童B型肝炎病毒感染率調查暨B型肝炎防治(接種LGVAC-B疫苗)成效評估
- The Prevalence and Its Meaning of Anti-HBc alone 15 Years Subsequent to Mass Hepatitis B Vaccination
- 談血液透析患者應如何接種B型肝炎疫苗
頁籤選單縮合
題 名 | 臺灣B型肝炎防治=Prevention and Control of Hepatitis B in Taiwan |
---|---|
作 者 | 劉嘉玲; 張秀芳; 黃志傑; 周玉民; 周玉民; 張秀芳; 劉嘉玲; 黃志傑; | 書刊名 | 疫情報導 |
卷 期 | 32:14 2016.07.19[民105.07.19] |
頁 次 | 頁290-300 |
分類號 | 412.471 |
關鍵詞 | B型肝炎防治; B型肝炎疫苗; |
語 文 | 中文(Chinese) |
中文摘要 | 臺灣自1982年開始推動「加強B型肝炎防治第一期計畫」,已實施6期中程計畫,並於2011年起併於「急性傳染病流行風險監控與管理計畫」接續執行防治工作,同時維持B型肝炎疫苗高接種完成率、提升肝炎篩檢率及擴大治療人數等措施。臺灣於1984年7月全球首創推動國家大規模孕婦B型肝炎篩檢及嬰幼兒B型肝炎預防接種計畫,使得國內B型肝炎母嬰垂直感染獲得相當有效之阻斷,並引領世界各國跟進。而我國6歲幼兒B型肝炎帶原率亦由未實施預防注射前之10.5%,大幅下降至2007年之0.8%,並達到世界衛生組織西太平洋區域辦事處(WHO Western Pacific Region, WPRO)所訂2017年小於1%之目標。然現今B型肝炎防治工作仍面臨諸多挑戰,包括:高傳染性母親所生小孩中,仍有近10%無法經由預防接種阻斷感染;B型肝炎疫苗並非終身免疫,如抗體消失,且有高危險行為,其感染的風險仍在;國內慢性B型肝炎人數仍多,可能不瞭解自身帶原狀況而傳染他人;B型肝炎可以控制,但仍無法治癒等。雖然B型肝炎已逐漸擺脫國病的威脅,但未來仍需各界繼續努力,陸續突破目前所面臨的防治課題。 |
英文摘要 | Taiwan government initiated the Hepatitis B Control Program in 1982, and a series of five-year programs had been subsequently proposed and enacted. In 2011, Hepatitis B Control Program has been integrated into the Acute Infectious Disease Epidemic Risk Monitoring and Management Plan. The main strategies for Hepatitis B control include maintaining high vaccination rate, increasing hepatitis testing, and extending hepatitis treatment. A nationwide screening of pregnant women and neonate mass immunization program against hepatitis B has been implemented since July 1984. That program significantly reduced mother-to-child transmission of hepatitis B virus in Taiwan. The HBsAg positive rate of children at age six years has declined from 10.5% before the immunization program to 0.8 % in 2007, which has reached the WPRO 2017 goal of hepatitis B prevalence among young children to less than 1%. Nowadays, we still face several challenges to control hepatitis B. Immunization cannot interrupt all vertical transmissions of hepatitis B virus. Among infants born to HBeAg positive mothers, 10% will become chronic carriers of hepatitis B after even receiving immunoprophylaxis. The Hepatitis B vaccination does not provide life-long protection; therefore, vaccinees who had lost protective antibodies but had high risk behaviors may be infected with HBV if exposed. Moreover, there are numerous people living with chronic hepatitis B but unaware of their infection status and may unknowingly spread the virus to others. In addition, treatments for hepatitis B can suppress HBV replication but cannot cure the disease. We expect the above issues could be resolved in the future and look forward to further breakthroughs in hepatitis B control. |
本系統中英文摘要資訊取自各篇刊載內容。